Dr. Tkaczuk on the Utilization of Trastuzumab Deruxtecan in HER2+ Breast CancerByKatherine Tkaczuk, MDOctober 5th 2022Katherine Tkaczuk, MD, discusses the utilization of trastuzumab deruxtecan in HER2-positive breast cancer.